🔴 Lantern Pharma is trading 5.7% down with no confirmed company-specific catalyst

Lantern Pharma is trading 5.7% down at $1.15 on September 28, 2026, with no confirmed company-specific catalyst explaining the decline.

• The September 22 patent allowance announcement does not establish a cause for the decline.
• Broader markets are weaker, with oil prices and Treasury yields rising after President Trump rejected Iran’s proposal.
• Major indices are down, but the supplied market context does not establish that macro conditions directly caused Lantern Pharma’s move.